Head-to-head evidence
AV-1959R vs SHR-1707
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Amyloid-beta (monoclonal antibody) · full Alzheimer's Disease pipeline
AV-1959R
Developed by Nuravax, Inc.
NCT06831812 · Phase 1 · completed
The trial was randomized and blinded with a placebo comparator, but it enrolled only 16 people in total, with as few as two per placebo group, and it was designed to test safety and antibody response rather than a disease outcome. No serious adverse events occurred in any group, but the very small numbers mean the safety comparison cannot rule much out.
Next expected readout: June 2029 · NCT07827768 (registry estimate)
SHR-1707
Developed by Jiangsu Hengrui Pharmaceuticals
NCT05681819 · Phase 1 · completed
The trial randomized 33 participants to SHR-1707 or placebo with triple-blinding, a design able to isolate a genuine drug effect, but its primary outcomes were safety measures rather than a cognitive or functional efficacy endpoint, and results have not yet been posted, so no effect on Alzheimer's disease could be established from this record.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AV-1959R's landscape · SHR-1707's landscape